Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors

Acta Radiologica

Volumn 51, Issue 7, 2010, Pages 793-799

  Abramyuk, Andrij ^a   Wolf, Gunter ^a   Shakirin, Georgy ^b   Haberland, Ulrike ^c   Tokalov, Sergey ^a   Koch, Arne ^a   Appold, Steffen ^d   Zphel, Klaus ^d   Abolmaali, Nasreddin ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c SIEMENS AG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cancer; Lacunarity; Prognosis; Tumor blood supply

Indexed keywords

18-F-FLUORODEOXYGLUCOSE; BLOOD SUPPLY; CANCER; COMPLEMENTARY METHODS; CT IMAGE; DYNAMIC CONTRAST; FDG-PET; HEAD-AND-NECK TUMOR; INFORMATION CONCERNING; LACUNARITY; LOCAL RECURRENCE; OUTCOME PREDICTION; OVERALL SURVIVAL; PATLAK ANALYSIS; PEARSON COEFFICIENT; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; PRE-TREATMENT; PRELIMINARY ASSESSMENT; PROGNOSIS; PROGNOSIS PREDICTION; STANDARDIZED UPTAKE VALUES; TUMOR BLOOD VOLUME; TUMOR HETEROGENEITY; WEAK CORRELATION;

BLOOD; DOSIMETRY; FORECASTING; PIXELS; POSITRON EMISSION TOMOGRAPHY; TUMORS;

COMPUTERIZED TOMOGRAPHY;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18; IOHEXOL; IOPROMIDE; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HEAD AND NECK TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; VASCULARIZATION;

AGED; CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; IOHEXOL; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955685628     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.3109/02841851.2010.491092     Document Type: Article

References (35)

1. Gordin A, Golz A, Daitzchman M, Keidar Z, Bar-Shalom R, Kuten A, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys 2007;68:370-376
2. Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg 2007;137:130-137
3. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006;6:51.
4. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130:1361-1367
5. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20: 1398-1404
6. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004;59:1295-1300
7. Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB, et al. 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 2007;33:790-795
8. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56-68.
9. Davies A, Tan C, Paschalides C, Barrington SF, O'Doherty M, Utley M, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007;55:75-78
10. Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007;48:752-757
11. Abramyuk A, Tokalov S, Zophel K, Koch A, Szluha Lazanyi K, Gillham C, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 2009;91:399-404.
12. Rumboldt Z, Al-Okaili R, Deveikis JP. Perfusion CT for head and neck tumors: pilot study. Am J Neuroradiol 2005;26:1178-1185
13. Zima A, Carlos R, Gandhi D, Case I, Teknos T, Mukherji SK. Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? Am J Neuroradiol 2007;28:328-334
14. Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. Pathophysiology of tumor neovascularization. Vasc Health Risk Manag 2005;1:277-290
15. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-458
16. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984;10: 695-712.
17. Plotnick RE, Gardner RH, Hargrove WW, Prestegaard K, Perlmutter M. Lacunarity analysis: a general technique for the analysis of spatial patterns. Phys Rev E 1996;53: 5461-5468
18. Smith TG Jr, Lange GD, Marks WB. Fractal methods and results in cellular morphology -dimensions, lacunarity and multifractals. J Neurosci Methods 1996;69:123-136
19. Rasband WS. ImageJ, version 1.41o, US National Institutes of Health, Bethesda, USA, 1997 -2008 (http://rsb.info.nih. gov/ij/).
20. Karperien A. FracLac for ImageJ, version 2.5, 1999 -2007 (http://rsb.info.nih.gov/ij/plugins/fraclac/FLHelp/Introduction. htm).
21. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87.
22. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015-1024
23. Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F] FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977-984
24. Schutze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 2007; 83:311-315
25. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13:3255-3263
26. Torizuka T, Tanizaki Y, Kanno T, Futatsubashi M, Naitou K, Ueda Y, et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. Am J Roentgenol 2009;192:W156 -60.
27. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-1356
28. Lartigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R, et al. Oxygenation of head and neck tumors. Cancer 1993;71:2319-2325
29. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
30. Cao M, Liang Y, Shen C, Miller K, Stantz K. Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with differing angiogenic phenotype. IEEE Trans Med Imaging 2009;28:861-871
31. Bisdas S, Spicer K, Rumboldt Z. Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: a pilot study using combined positron-emission tomography/CT imaging. Am J Neuroradiol 2008;29:1376-1381
32. Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:22-28
33. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006;80:151-156
34. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270
35. Kallinowski F, Schlenger KH, Kloes M, Stohrer M, Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer 1989;44:266-272